Expanded partnership to help increase patient
access to critical genetic screening services including genetic
counseling and test result turnaround time
HOUSTON, March 29,
2024 /PRNewswire/ -- The Prelude
Network® (Prelude), the largest network of
fertility clinics in North
America, announced today an expansion of its partnership
with Labcorp (NYSE: LH), a global leader of innovative
diagnostic and biopharma laboratory services, to serve as its
Preferred Genetic Carrier Screening Lab.
Labcorp has long been a partner to Prelude and its expansive
network of more than 90 clinics across the U.S. and in parts of
Canada, providing clinical
laboratory and FDA-approved donor testing within each clinic. The
expansion of this partnership delivers another level of genetic
carrier screening services to Prelude patients, including in-office
phlebotomists and patient service centers. Additionally, Labcorp
offers comprehensive genetic counseling, services for provider
questions, and complimentary review of carrier screening results
for patients. It also capitalizes on a pre-existing interface with
electronic medical records for ordering and reporting carrier
screening results, improved clarity on reports with
variant-specific interpretation, and highly competitive network
contract rates for other genetic tests. To improve financial access
to genetic carrier screening for the U.S. patient population,
Labcorp is contracted with many insurance companies.
"Genetic screening is a vital part of fertility diagnostics as
it helps patients and physicians make critical decisions on care
and treatment options that lead to optimal outcomes," says TJ
Farnsworth, Founder and CEO of Inception
Fertility™, the parent company to The Prelude Network.
"By expanding our partnership with Labcorp, we're able to deliver a
higher level of care to those patients who require genetic
screening services to build their families, and we're excited to
work closely with Labcorp to improve accessibility and the patient
experience."
This expanded partnership also supports Prelude's Genetic Center
of Excellence program and its commitment to offering best-in-class
services to patients incorporating genetic testing as part of their
care plans. Launched in 2022, one of the initiatives of the Genetic
Center of Excellence is to establish standardized, high-quality
genetic screening for patients and egg donors in Prelude's
network.
"Prelude is excited to offer our patients greater access to
best-in-class genetic carrier screening," says Lauri Black, Certified Genetic Counselor and
Director of Genetic Services at Inception. "It is our belief that
by appointing Labcorp as The Prelude Network's Preferred Genetic
Carrier Screening Lab, we can build on our efforts to give every
aspiring parent a greater chance at bringing home a healthy
baby."
To learn more about Prelude clinics, that span across the US and
part of Canada, please
visit preludefertility.com.
About The Prelude Network®
The Prelude Network® (Prelude), the fastest-growing
network of fertility clinics and largest provider of comprehensive
fertility services in North
America, is the clinic network of Inception
Fertility™ – a family of fertility brands that touches
every part of the fertility journey, including diagnostics and
treatment to financial accessibility.
Each clinic, as part of Prelude, is committed to delivering the
highest level of personalized fertility care by the nation's
leading reproductive endocrinologists, embryologists and
practitioners by focusing on an excellence in science, medicine and
the patient experience. The growing Prelude Network has more than
90 total locations nationwide, offering a wide range of fertility
services including egg freezing, IVF, genetic testing, LGBTQ+
fertility options, and egg/embryo storage, among others.
Those clinics within Prelude include Aspire Fertility Austin
(Texas); Aspire Fertility Dallas
(Texas); Aspire Fertility McAllen
(Texas); Aspire Fertility San
Antonio (Texas); Aspire Houston
Fertility Institute (Texas);
Advanced Fertility Center of Chicago (Illinois); Center for Reproductive Medicine
(Florida); Indiana Fertility
Institute (Indiana); IVFMD
(Florida); Main Line Fertility
(Pennsylvania); NYU Langone
Fertility Center (New York); NYU
Langone RSNY (New York); Pacific
Centre for Reproductive Medicine
(Canada); Pacific Fertility Center
(California); Regional Fertility
Program (Canada); Reproductive
Biology Associates (Georgia);
Tennessee Fertility Institute (Tennessee), and The Reproductive Medicine
Group (Florida).
About Inception Fertility™
Inception
Fertility™ (Inception) is a family of fertility brands
committed to helping patients build their own families. Built by
patients for patients, Inception's purpose is to achieve the
highest bar in experience, science and medicine in an effort to
enhance each patient's experience and achieve better
outcomes.
Inception's medical experts are leading pioneers in fertility
care. Our doctors are some of the first to use breakthrough
assisted reproductive technologies (ART) – including in vitro
fertilization (IVF), preimplantation genetic testing (PGT) and
fertility preservation services – and they continue to lead the
industry by building on these technologies by through development,
research and thought leadership.
Through its growing family of national organizations – which
includes The Prelude Network®, the fastest-growing
network of fertility clinics and largest provider of comprehensive
fertility services in North America; Pathways Fertility,
clinics that provide affordable, individualized and high quality
care; MyEggBank®, one of the largest frozen donor
egg banks in North America; BUNDL Fertility™, a
multi-cycle fertility service bundling
program; HavenCryo™, a long-term reproductive
preservation and storage solution provider
and NutraBloom®, a premium lifestyle brand with
expertly formulated supplements to support individuals' health and
wellness goals for preconception – Inception is working to deliver
on its promise to push the envelope of what is possible for
exceeding patient expectations.
About Labcorp
Labcorp (NYSE: LH) is a global
leader of innovative and comprehensive laboratory services that
helps doctors, hospitals, pharmaceutical companies, researchers and
patients make clear and confident decisions. We provide insights
and advance science to improve health and improve lives through our
unparalleled diagnostics and drug development laboratory
capabilities. The company's more than 67,000 employees serve
clients in over 100 countries, worked on over 84% of the new drugs
approved by the FDA in 2023 and performed more than 600 million
tests for patients around the world. Learn more about us
at www.labcorp.com.
Media Contact:
Mia
Humphreys
239-297-6592
MHumphreys@kruppagency.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-prelude-network-names-labcorp-its-preferred-genetic-carrier-screening-lab-302103351.html
SOURCE The Prelude Network